Post-earnings recap
Reported
Thu, Aug 6, 2026
EPS actual
$3.23
EPS est.
$3.14
EPS surprise
+2.96%
1-day move
+3.76%
Becton, Dickinson's earnings report showed a positive surprise in EPS, which contributed to a 3.76% increase in stock price. However, with no revenue data provided, investors may be cautious about the overall performance. The lack of management commentary and guidance leaves some uncertainty about future expectations.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $3.23 | N/A | +2.96% |
| Revenue | N/A | N/A | N/A |
No transcript is on record, and the analysis is based on numerical results only.
Becton, Dickinson and Company (BDX) is a leading global medical technology company that develops and manufactures a wide range of medical devices, instrument systems, and reagents. Operating in the Health Care sector, BDX plays a crucial role in improving patient outcomes and enhancing the efficiency of healthcare delivery.
Last quarter
In Q2 2026, BDX reported an EPS of $2.90, exceeding expectations by 4.73%. The stock reacted positively, gaining 5.87% the following day.
EPS beat streak
8Q
EPS beat rate
100%
Avg EPS surprise
+4.62%
Avg 1-day reaction
-0.58%
Overall, the market is cautiously optimistic about BDX's upcoming earnings report, especially given its consistent EPS beats in recent quarters.
Bull case
If BDX continues its trend of beating EPS estimates, it could signal strong operational performance and market demand, leading to a significant stock price increase.
Bear case
Conversely, if the company fails to meet expectations or provides weak guidance, it could raise concerns about its growth prospects, resulting in a negative market reaction.
The print will turn on these.
Q1
What will the EPS be this quarter?
Given BDX's history of beating EPS estimates, the actual EPS figure will be critical in determining market sentiment post-earnings.
Q2
How does management view revenue growth in key segments?
Insights into revenue growth in critical areas will help investors gauge the company's market position and future outlook.
—
Est. EPS
$0.11
Est. Rev
$4.8B
Impl. Move
±18.7%
Why consensus could be wrong
The Street may be underestimating BDX's ability to sustain its growth trajectory, particularly in emerging markets where demand for medical devices is increasing.
Supporting evidence
BDX has consistently beaten EPS estimates, indicating stronger-than-expected performance.
Options pricing suggests a higher volatility expectation than historical averages, which could reflect underlying strength.
Recent trends in healthcare spending may support continued demand for BDX's products.
Key risk
If BDX reports revenue growth above expectations, it could challenge the current cautious consensus.
Pre-commit to what would confirm each case.
The market is weighing BDX's ability to maintain its growth trajectory amid competitive pressures and economic conditions.
Bull confirmed if
A reported EPS above $2.90 would confirm the bull case and indicate strong operational performance.
Bear confirmed if
An EPS below $2.80 would signal potential weakness and confirm the bear case.
What the market is pricing for the move.
Implied Move
±12.03%
Historical Avg
±5.6%
The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.
Options are pricing ±12.0% while BDX has averaged ±5.6% over the last 8 prints — setup is pricing rich.
ATM IV
0.3%
30d HV
32.1%
Smart-money positioning from the most recent 13F filings.
Institutional
99.78%
of float
Insider
0.43%
of float
Holders
1,920
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
24,592,166 sh · $4.4B
8.93%
-6.0%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If BDX beats expectations, history suggests a stock price increase of around 5.41%, confirming strong operational performance.
In line / cautious
If results are in line with expectations, the stock may experience a muted reaction as investors await further guidance.
Miss
A miss could lead to a decline in stock price, with historical patterns suggesting an average drop of around 1.31%.
House and Senate STOCK Act disclosures over the trailing 6 months.
Trades
1
0 buys·1 sell
Members
1
House only
Est. Notional
$1,001.00–$15,000.00
disclosed dollar ranges
Most Active Members
1 trade
The lines on the call that would change the story.
Vanguard Capital Management LLC
17,987,834 sh · $3.2B
6.53%
-2.7%
State Street Corporation
15,000,064 sh · $2.7B
5.44%
8.5%
Vanguard Portfolio Management LLC
14,974,136 sh · $2.7B
5.43%
-2.2%
First Eagle Investment Management, LLC
13,815,335 sh · $2.5B
5.01%
15.8%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.
Net selling
Recent Transactions
Traded May 21, 2026 · disclosed Jun 18, 2026
$1,001.00–$15,000.00
Filed 30–45+ days after the trade. Treat as positional context, not a leading indicator. Amounts are SEC-mandated dollar ranges, not exact values.